Press Releases
| [+] |
November 13, 2008 Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated San Diego, CA – November 13, 2008 – Ambrx Inc. today announced Phase I/II clinical trial data demonstrating that ARX201, the company’s long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I (IGF-I) levels while delivering an acceptabl… Read More |
|
| [+] |
February 26, 2008 Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development San Diego, CA – February 26, 2008 – Ambrx Inc. today announced the appointment of Douglas W. Axelrod, M.D., Ph.D., as Senior Vice President for Clinical Research and Development. Axelrod joins Ambrx after a productive career spanning nearly two decades at Procter & Gamble Pharmaceuticals. Mos… Read More |
Articles
- April 1, 2005
Unnatural Amino Acid Could Prove Boon for Protein Therapeutics
Science Magazine - March 14, 2005
Giving Biotechnology A Chemical Push
Chemical & Engineering News - March 14, 2005
Watching Peptide Drugs Grow Up
Chemical & Engineering News - January 12, 2004
The Code Breakers
Bio-IT World - October 6, 2003
Executive Profile - RICHARD D. DIMARCHI
SD Business Journal (paid access) - September 29, 2003
Ambrx Inc. Lands $12.5M in First-Round Funding
SD Business Journal (paid access) - September 23, 2003
First-Round Financing of $12.5M Puts Ambrx On Development Path
BioWorld Today - September 22, 2003
Schultz seeks another success with Ambrx
The Daily Deal
